Pancreatic Cancer Research

Clinical trialPhase 2Terminated

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

BrafPanc: A Phase II Trial of Binimetinib in Combination With Encorafenib in Patients With Pancreatic Malignancies and a Somatic BRAFV600E Mutation

Outcome
Stopped early. Results posted; single-arm, no comparisonSlow accrual (Enrollment)
Phase
Phase 2
Status
Terminated
Study type
Interventional
Start
16 November 2020
Ended
1 November 2023
Enrollment
6 participants
Sites
5
Primary outcomes
Objective Response Rate (ORR) at 24 Weeks
Sponsor type
Academic / other
Results posted
23 January 2024
Last update
6 May 2024

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Results

Primary endpoint
Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 6 May 2024
ORR
Objective Response Rate (ORR) at 24 WeeksTreatment (Encorafenib, Binimetinib): 33.33 (4.33 to 77.72), n = 6Values: percentage of patients, 95% Confidence IntervalTime frame: 24 weeksNo analysis posted for this outcome (outcome 1)
Participants
Treatment (Encorafenib, Binimetinib): 6 started, 0 completed
Serious adverse events
Treatment (Encorafenib, Binimetinib): 1 of 6Participants with at least one serious adverse event, of those at risk, as posted
5 secondary outcomes
PFS · Progression-free Survival (PFS)
Treatment (Encorafenib, Binimetinib) 7.1 (1.7 to NA), n=6 [median months, 95% Confidence Interval]
OS · Overall Survival
Treatment (Encorafenib, Binimetinib) 15.0 (3.1 to NA), n=6 [median months, 95% Confidence Interval]
Duration of Response
Treatment (Encorafenib, Binimetinib) 9.9 (8.5 to NA), n=3 [median months, 95% Confidence Interval]
Time to Response
Treatment (Encorafenib, Binimetinib) 3.9 (3.6 to NA), n=6 [median months, 95% Confidence Interval]
Number of Patients With Grade 3+ Adverse Events
Treatment (Encorafenib, Binimetinib) 3/6 [Participants]

Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This phase II trial studies the side effects and how well the combination of binimetinib and encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may work better compared to the usual treatment in treating patients with pancreatic cancer and a somatic BRAF V600E mutation.

Detailed description public domain (ClinicalTrials.gov)

PRIMARY OBJECTIVE: I. To determine the efficacy of the combination of binimetinib and encorafenib as \>= 2nd line of treatment for patients with metastatic pancreatic cancer with BRAF V600E mutation. SECONDARY OBJECTIVES: I. To determine in patients treated with the combination of binimetinib and encorafenib as \>= 2nd line of treatment for patients with metastatic pancreatic cancer with BRAF V600E mutation: Ia. The median progression-free survival. Ib. The median overall survival. Ic. Duration of response. Id. Time to response. Ie. The safety and tolerability. OUTLINE: Patients receive encorafenib orally (PO) once daily (QD) and binimetinib PO twice daily (BID) on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for up to 5 years.

Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)

Objective Response Rate (ORR) at 24 Weeks [24 weeks]. Number, percentage of patients (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 33.33 (4.33 to 77.72).

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Progression-free Survival (PFS) [25 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 7.1 (1.7 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Overall Survival [25 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 15.0 (3.1 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Duration of Response [12 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=3): 9.9 (8.5 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Time to Response [25 months]. Median, months (95% Confidence Interval). Treatment (Encorafenib, Binimetinib) (n=6): 3.9 (3.6 to NA) [The upper limit of the confidence interval was not estimatable due to an insufficient number of participants with events].

Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)

Number of Patients With Grade 3+ Adverse Events [25 months]. Count Of Participants, Participants. Treatment (Encorafenib, Binimetinib) (n=6): 3.